As you will be aware the Department for Health and Social Care has asked NICE to carry out a Single Technology Appraisal of encorafenib in combination with binimetinib for treating advanced (unresectable or metastatic) BRAF V600 mutation-positive melanoma.
Following on from advice received from the company, the appraisal is now expected to start in approximately mid June 2018 when we will write to you about how you can get involved. The deadline for submissions is expected in approximately mid August 2018.